Glucose Concentration in the Dialysate does not Contribute to Lipid Profiles in Patients Undergoing CAPD

REFERENCES

• Prichard S. Cardiac disease in dialysis patients: Dyslipidemia as a risk factor. Semin Dial. 1999;12:87–90.
   Google Scholar
• Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The Uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis. 1992;20:324–335.
   Google Scholar
• Elisof M, Mikhailidis DP, Siampoulos KC. Dyslipidemia in patients with renal disease. J Drug Dev Clin Pract. 1996; 17:331–348.
   Google Scholar
• Kronenberg F, Konig P, Neyer U, Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–120.
   PubMed Web of Science ®Google Scholar
• Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis. Perit Dial Int. 1995;15:342–347.
   PubMedGoogle Scholar
• Llopart R, Donate T, Oliva JA, Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant. 1995;10:537–540.
   PubMed Web of Science ®Google Scholar
• Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci. 2009;11:201–212.
   PubMedGoogle Scholar
• Fytili CI, Progia EG, Panagoutsos SA, Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2002;24:623–630.
   PubMed Web of Science ®Google Scholar
• Lobos JM, Royo-Bordonada MA, Brotons C, European guidelines on cardiovascular disease prevention in clinical practice: CEIPC 2008 Spanish adaptation. Rev Esp Salud Publica. 2008;82:581–616.
   Google Scholar
• Nishizawa Y, Shoji T, Kakiya R, Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int. 2003;(Suppl.):S117–S120.
   Google Scholar
• Gault MH, Longerich L, Prabhakaran V, Purchase L. Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans. 1991;37:M513–M514.
   Google Scholar
• Docci D, Bilancioni R, Turci F, Baldrati L. Hyperlipidemia in uremic patients in dialysis. Quad Sclavo Diagn. 1985; 21:424–429.
   Google Scholar
• Onat A, Can G, Hergen G, Yazıcı M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes. 2007;31:1119–1125.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, for the INTERHEART Study Investigators. Effect of potencially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): Case-control study. Lancet. 2004;364:937–952.
   PubMed Web of Science ®Google Scholar
• Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: Metaanalysis of prospective studies. Clin Chem. 1998;44:2301–2306.
   PubMed Web of Science ®Google Scholar
• Dieplinger H, Kronenberg F. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). Wien Klin Wochenschr. 1999;111: 5–20.
   Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112–S119.
   PubMed Web of Science ®Google Scholar
• US Renal Data System. Experts from the USRDS 2005 Anuual data report: Atlas of end-stage renal disease in the United States, national institutes of health, national institute of diabetes and digestive and kidney diseases. Am J Kidney Dis. 2006;47(Suppl. 1):S1–S286.
   Google Scholar
• Young GA, Kopple JD, Lindholm B, Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study. Am J Kidney Dis. 1991;17(4):462–471.
   PubMed Web of Science ®Google Scholar
• Kamyar KZ, Morton K, Eileen D. A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant. 1999;14:1732–1738.
   Google Scholar
• Tan D, Fein PA, Antignani A, Mittman N, Avram MM. The impact of CAPD treatment on lipid metabolism and cardiovascular risk. Adv Perit Dial. 1990;6:233–237.
   Google Scholar
• Tamashiro M, Iseki K, Sunagawa O, Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001;38(1):64–69.
   PubMed Web of Science ®Google Scholar
• Burrell D, Antignani A, Fein PA, Goldwasser P, Mittman N, Avram MM. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients. ASAIO Trans. 1990;36(3): M331–M335.
   Google Scholar
• Kwan BD, Bonnie CHK, Florian K, Srinivasan B. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–1261.
   Google Scholar
• Burrell DE, Antignani A, Goldwasser P, Lipid abnormalities in black renal patients. N Y State J Med. 1991;91: 192–196.
   Google Scholar
• Yiğitoğlu MR, Polat MF, Akçay F, Ari Z, Uyanik BS, Ozilgili HM. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis. Jpn Heart J. 1997;38:83–89.
   Google Scholar
• Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis. 1992;20:324–335.
   Google Scholar
• Tumer RC, Millns H, Neal HA, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998;316:823–828.
   Google Scholar
• Harris SB, EkoéJ M, Zdanowicz Y, Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract. 2005;70:90–97.
   PubMed Web of Science ®Google Scholar
• Yung S, Chen XR, Tsang RC, Zhang Q, Chan TM. Reduction of perlecan synthesis and induction of TGF-β1 in human peritoneal mesothelial cells dues to high dialysate glucose concentration: Implication in peritoneal dialysis. J Am Soc Nephrol. 2004;15:1178–1188.
   Google Scholar